Targeting the fetal acetylcholine receptor in rhabdomyosarcoma

Expert Opinion on Therapeutic Targets

Volumn 17, Issue 2, 2013, Pages 127-138

  Simon Keller, Katja ^a   Barth, Stefan ^b,c   Vincent, Angela ^d   Marx, Alexander ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Acetylcholine receptor; Fetal; Immune therapy; Rhabdomyosarcoma

Indexed keywords

BACTERIAL TOXIN; FETAL NICOTINIC ACETYLCHOLINE RECEPTOR; IMMUNOTOXIN; NICOTINIC RECEPTOR; ONCOLYTIC VIRUS; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY 35 EXOTOXIN A; UNCLASSIFIED DRUG;

AUTOIMMUNITY; CANCER PREVENTION; EMBRYONAL RHABDOMYOSARCOMA; HUMAN; IMMUNOTHERAPY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; RHABDOMYOSARCOMA;

ANIMALS; FETUS; HUMANS; IMMUNOTHERAPY; RECEPTORS, CHOLINERGIC; RHABDOMYOSARCOMA; SOFT TISSUE NEOPLASMS;

EID: 84872231618     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2013.734500     Document Type: Review

References (120)

1. Huh W, Skapek S. Childhood rhabdomyosarcoma: new insight on biology and treatment. Curr Oncol Rep 2010;12:402-10
2. Koscielniak E, Morgan M, Treuner J. Soft tissue sarcoma in children: Prognosis and management. Pediatric Drugs 2002; 4:21-8 (Pubitemid 34208343)
3. Ferrari A, Sultan I, Huang TT, et al. Soft tissue sarcoma across the age spectrum: A population-based study from the surveillance epidemiology and end results database. Pediatr Blood Cancer 2011;57(6):943-9
4. Saab R, Spunt SL, Skapek SX, Michael AD. Myogenesis and rhabdomyosarcoma: The jekyll and hyde of skeletal muscle. current topics in developmental biology. Academic Press 2011;197-234
5. Parham DM, Ellison DA. Rhabdomyosarcomas in adults and children: An update. Arch Pathol Lab Med 2006;130:1454-65 (Pubitemid 44520712)
6. Jothi M, Nishijo K, Keller C, Mal AK. AKT and PAX3-FKHR cooperation enforces myogenic differentiation blockade in alveolar rhabdomyosarcoma cell. Cell Cycle 2012;11:895-908
7. Collins CA, Gnocchi VF, White RB et al. Integrated functions of pax3 and pax7 in the regulation of proliferation cell size and myogenic differentiation. PLoS One 2009;4:e4475
8. Calhabeu F, Hayashi S, Morgan JE et al. Alveolar rhabdomyosarcomaassociated proteins PAX3/FOXO1A and PAX7/FOXO1A suppress the transcriptional activity of MyoD-target genes in muscle stem cells. Oncogene 2012; [Epub ahead of print]
9. Tiffin N, Williams RD, Shipley J Pritchard-Jones K. PAX7 expression in embryonal rhabdomyosarcoma suggests an origin in muscle satellite cells. Br J Cancer 89:327-32
10. Riggi N, Cironi L, Suva ML Stamenkovic I. Sarcomas: genetics signalling, and cellular origins. Part 1: The fellowship of TET. J Pathol 2007; 213:4-20 (Pubitemid 47354561)
11. Merlino G, Khanna C. Fishing for the origins of cancer. Genes Dev 2007; 21:1275-9 (Pubitemid 46871031)
12. Hayes-Jordan A, Andrassy R. Rhabdomyosarcoma in children. Curr Opin Pediatr 2009;21:373-8
13. Stock NM, Chibon F, Nguyen Binh MB, et al. Adult-type rhabdomyosarcoma: Analysis of 57 cases with clinicopathologic description identification of 3 morphologic patterns and prognosis. Am J Surg Pathol 2009; 33:1850-9
14. Chibon F, Lagarde P, Salas S, et al. Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med 2010;16:781-7
15. Wachtel M, Runge T, Leuschner I, et al. Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry. J Clin Oncol 2006;24:816-22 (Pubitemid 46622049)
16. Davicioni E, Anderson MJ, Finckenstein FG, et al. Molecular classification of rhabdomyosarcoma-genotypic and phenotypic determinants of diagnosis: A report from the children's oncology group. Am J Pathol 2009;174:550-64
17. Ho RH, Johnson J, Dev VG, Whitlock JA. A novel t(2;20)(q35;p12) in embryonal rhabdomyosarcoma. Cancer Genet Cytogenet 2004;151:73-7 (Pubitemid 38569635)
18. Meloni-Ehrig A, Smith B, Zgoda J, et al. Translocation (2;8)(q35;q13): A recurrent abnormality in congenital embryonal rhabdomyosarcoma. Cancer Genet Cytogenet 2009;191:43-5
19. Gallego Melcon S, Sanchez de Toledo Codina J. Molecular biology of rhabdomyosarcoma. Clin Transl Oncol 2007;9:415-19
20. Rezvani G, Lui JCK, Barnes KM, Baron J. A set of imprinted genes required for normal body growth also promotes growth of rhabdomyosarcoma cells. Pediatr Res 2012;71:32-8
21. Anderson J, Gordon A, McManus A et al. Disruption of imprinted genes at chromosome region 11p15.5 in paediatric rhabdomyosarcoma. Neoplasia 1999;1:340-8
22. Sorensen PHB, Lynch JC, Qualman SJ et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: A report from the childrens oncology group. J Clin Oncol 2002;20:2672-9 (Pubitemid 34575640)
23. Olguin HC, Pisconti A. Marking the tempo for myogenesis: Pax7 and the regulation of muscle stem cell fate decisions. J Cell Mol Med 2012;16:1013-25
24. Bois PRJ, Izeradjene K, Houghton PJ et al. FOXO1a acts as a selective tumor suppressor in alveolar rhabdomyosarcoma. J Cell Biol 2005;170:903-12 (Pubitemid 41306290)
25. Anderson J, Ramsay A, Gould S Pritchard-Jones K. PAX3-FKHR induces morphological change and enhances cellular proliferation and invasion in rhabdomyosarcoma. Am J pathol 2001; 159:1089-96 (Pubitemid 32847199)
26. Higano CS, Schellhammer PF, Small EJ et al. Integrated data from 2 randomized double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009;115:3670-9
27. Reimann J, Jacobson L, Vincent A Kornblum C. Endplate destruction due to maternal antibodies in arthrogryposis multiplex congenita. Neurology 2009; 73:1806-8
28. Carli M, Colombatti R, Oberlin O, et al. European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors. J Clin Oncol 2004;22:4787-94
29. Stevens MCG, Rey A, Bouvet N, et al. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: Third Study of the International Society of Paediatric Oncology-SIOP malignant mesenchymal tumor 89. J Clin Oncol 2005;23:2618-28 (Pubitemid 46179450)
30. Crist WM, Anderson JR, Meza JL, et al. Intergroup rhabdomyosarcoma study-iv: Results for patients with nonmetastatic disease. J Clin Oncol 2001;19:3091-102 (Pubitemid 32567502)
31. Walterhouse D, Watson A. Optimal management strategies for rhabdomyosarcoma in children. Pediatric Drugs 2007;9:391-400 (Pubitemid 350208913)
32. Spunt SL, Smith LM, Ruymann FB et al. cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome. Clin Cancer Res 2004;10:6072-9
33. Breneman JC, Lyden E, Pappo AS, et al. Prognostic Factors and Clinical Outcomes in Children and Adolescents With Metastatic Rhabdomyosarcoma-A Report From the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 2003;21:78-84
34. Pappo AS, Anderson JR, Crist WM et al. Survival after relapse in children and adolescents with rhabdomyosarcoma: A report from the intergroup rhabdomyosarcoma study group. J Clin Oncol 1999;17:3487-93 (Pubitemid 29517919)
35. Doelken R, Weigel S, Schueler F, et al. Poor outcome of two children with relapsed state stage IV alveolar rhabdomyosarcoma after allogeneic stem cell transplantation. Pediatr Hematol Oncol 2005;22:699-703 (Pubitemid 41572165)
36. Gattenloehner S, Dockhorn-Dworniczak B, Leuschner I, et al. A Comparison of MyoD1 and fetal acetylcholine receptor expression in childhood tumors and normal tissues implications for the molecular diagnosis of minimal disease in rhabdomyosarcomas. J Mol Diagn 1999;1:23-31 (Pubitemid 129693358)
37. Albuquerque E, Pereira E, Alkondon M Scott W. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev 2009;89:73-120
38. Engel AG. Current status of the congenital myasthenic syndromes. Neuromuscul Disord 2012;22:99-111
39. Lukas RJ, Changeux J-P, le Novere N et al. International union of pharmacology. xx. current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol Rev 1999;51:397-401 (Pubitemid 29269984)
40. Karlin A, Cox RN, Dipaola M, et al. functional domains of the nicotinic acetylcholine receptora. Ann N Y Acad Sci 1986;463:53-69 (Pubitemid 16043142)
41. Vincent A, Jacobson L, Shillito P. Response to human acetylcholine receptor alpha138-199: Determinant spreading initiates autoimmunity to self-antigen in rabbits. Immunol Lett 1994;39:269-75 (Pubitemid 24123977)
42. Shyng S, Salpeter M. Effect of reinnervation on the degradation rate of junctional acetylcholine receptors synthesized in denervated skeletal muscles. J Neurosci 1990;10:3905-15
43. Sanes JR, Lichtman JW. Induction assembly, maturation and maintenance of a postsynaptic apparatus. Nat Rev Neurosci 2001;2:791-805 (Pubitemid 33674061)
44. Ruff RL. Neurophysiology of the neuromuscular junction: overview. Ann NY Acad Sci 2003;998:1-10 (Pubitemid 37194141)
45. Takeuchi A, Takeuchi N. On the permeability of end-plate membrane during the action of transmitter. J Physiol 1960;154:52-67
46. Wakkach A, Poea S, Chastre E, et al. Establishment of a human thymic myoid cell line: Phenotypic and functional characteristics. Am J Pathol 1999;155:1229-40 (Pubitemid 29488930)
47. Marx A, Willcox N, Leite M, et al. Thymoma and paraneoplastic myasthenia gravis. Autoimmunity 2010;43:413-27
48. Mehmood QU, Shaktawat SS, Parikh O. Case of rhabdomyosarcoma presenting with myasthenia gravis. J Clin Oncol 2011;29:e653-5
49. Fraterman S, Khurana TS, Rubinstein NA. Identification of acetylcholine receptor subunits differentially expressed in singly and multiply innervated fibers of extraocular muscles. Invest Ophthalmol Vis Sci 2006;47:3828-34 (Pubitemid 46044297)
50. Gattenloehner S, Vincent A, Leuschner I et al. The fetal form of the acetylcholine receptor distinguishes rhabdomyosarcomas from other childhood tumors. Am J Pathol 1998;152:437-44 (Pubitemid 28106390)
51. Walter D, Satheesha S, Albrecht P, et al. CD133 positive embryonal rhabdomyosarcoma stem-like cell population is enriched in rhabdospheres. PLoS One 2011;6:e19506
52. Hirotsu M, Setoguchi T, Matsunoshita Y, et al. Tumour formation by single fibroblast growth factor receptor 3-positive rhabdomyosarcoma-initiating cells. Br J Cancer 2009;101:2030-7
53. Kassar-Duchossoy L, Gayraud-Morel B Gomes D, et al. Mrf4 determines skeletal muscle identity in Myf5:myod double-mutant mice. Nature 2004; 431:466-71 (Pubitemid 39329587)
54. Rudnicki MA, Schnegelsberg PNJ, Stead RH, et al. MyoD or Myf-5 is required for the formation of skeletal muscle. Cell 1993;75:1351-9 (Pubitemid 24021909)
55. Mok GF, Sweetman D. Many routes to the same destination: lessons from skeletal muscle development. Reproduction 2011;141:301-12
56. Dahlqvist C, Blokzijl A, Chapman G et al. Functional notch signaling is required for BMP4-induced inhibition of myogenic differentiation. Development 2003;130:6089-99 (Pubitemid 38008810)
57. Gilmour BP, Fanger GR, Newton C et al. Multiple binding sites for myogenic regulatory factors are required for expression of the acetylcholine receptor gamma-subunit gene. J Biol Chem 1991;266:19871-4 (Pubitemid 21908397)
58. Sunyer T, Merlie JP. Cell type- and differentiation-dependent expression from the mouse acetylcholine receptor alpha-subunit promoter. J Neurosci Res 1993;36:224-34 (Pubitemid 23294151)
59. Durr I, Numberger M, Berberich C Witzemann V. Characterization of the functional role of e-box elements for the transcriptional activity of rat acetylcholine receptor epsilon-subunit and gamma-subunit gene promoters in primary muscle cell cultures. Eur J Biochem 1994;224:353-64 (Pubitemid 24282816)
60. Rota R, Ciarapica R, Giordano A, et al. MicroRNAs in rhabdomyosarcoma: Pathogenetic implications and translational potentiality. Mol Cancer 2011;10:120
61. Simon DJ, Madison JM, Conery AL et al. The microrna miR-1 regulates a MEF-2-dependent retrograde signal at neuromuscular junctions. Cell 2008;133:903-15 (Pubitemid 351707687)
62. Christianson JC, Green WN. Regulation of nicotinic receptor expression by the ubiquitin-proteasome system. EMBO J 2004;23:4156-65 (Pubitemid 39546154)
63. Poea-Guyon S, Christadoss P, Le Panse R, et al. Effects of cytokines on acetylcholine receptor expression: implications for myasthenia gravis. J Immunol 2005;174:5941-9 (Pubitemid 40663780)
64. Simon-Keller K, Mo-inger K, Bohlender A-L, et al. Variable resistance of RMS to INFgamma signaling. ISRN Oncol 2012;2012:789152
65. Gattenlohner S, Marx A, Markfort B et al. Rhabdomyosarcoma lysis by T cells expressing a human autoantibody-based chimeric receptor targeting the fetal acetylcholine receptor cancer res. 2006;66:24-8
66. Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet 2001; 357:2122-8 (Pubitemid 32607461)
67. Drachman DB. Myasthenia Gravis. N Engl J Med 1994;330:1797-810
68. Hohlfeld R, Wekerle H, Marx A. The immunopathogenesis of myasthenia gravis. In: Engel AG, editor. Myasthenia gravis and Myasthenic disorders. Oxford University Press; New York: 2012. p. 60-89
69. Giraud M, Taubert R, Vandiedonck C et al. An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus. Nature 2007;448:934-7 (Pubitemid 47312776)
70. Marx A, Hohenberger P, Hoffmann H et al. The autoimmune regulator AIRE in thymoma biology: Autoimmunity and beyond. J Thorac Oncol 2010;5:S266-72
71. Leite MI, Jones M, Strobel P, et al. Myasthenia gravis thymus: Complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status. Am J Pathol 2007;171:893-905 (Pubitemid 47440988)
72. Shiono H, Roxanis I, Zhang W, et al. Scenarios for autoimmunization of T and B cells in myasthenia gravis. Ann NY Acad Sci 2003;998:237-56 (Pubitemid 37194165)
73. Weinberg CB, Hall ZW. Antibodies from patients with myasthenia gravis recognize determinants unique to extrajunctional acetylcholine receptors. Proc Natl Acad Sci 1979. 76: 504-508 (Pubitemid 9106657)
74. Zisimopoulou P, Lagoumintzis G, Poulas K, Tzartos SJ. Antigen-specific apheresis of human anti-acetylcholine receptor autoantibodies from myasthenia gravis patients' sera using Escherichia coli-expressed receptor domains. J Neuroimmunol 2008;200:133-41
75. Tzartos SJ, Bitzopoulou K, Gavra I, et al. Antigen-specific apheresis of pathogenic autoantibodies from myasthenia gravis sera. Ann NY Acad Sci 2008;1132:291-9 (Pubitemid 351841360)
76. Vincent A, Newland C, Beeson D, et al. Arthrogryposis multiplex congenita with maternal autoantibodies specific for a fetal antigen. Lancet 1995;346:24-5
77. Monneaux F, Muller S. Epitope spreading in systemic lupus erythematosus: identification of triggering peptide sequences. Arthritis Rheum 2002;46:1430-8 (Pubitemid 34620187)
78. Wang H-B, Shi F-D, Li H, et al. Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis. J Immunol 2001;166:6430-6 (Pubitemid 32440778)
79. MacLennan CA, Vincent A, Marx A et al. Preferential expression of AChR epsilon-subunit in thymomas from patients with myasthenia gravis. J Neuroimmunol 2008;201:28-32
80. Curnow J, Corlett L, Willcox N, Vincent A. Presentation by myoblasts of an epitope from endogenous acetylcholine receptor indicates a potential role in the spreading of the immune response. J Neuroimmunol 2001;115:127-34 (Pubitemid 32245660)
81. Hill M, Beeson D, Moss P, et al. Early-onset myasthenia gravis: A recurring T-cell epitope in the adult-specific acetylcholine receptor epsilon subunit presented by the susceptibility allele HLA-DR52a. Ann Neurol 1999;45:224-31 (Pubitemid 29072369)
82. Kirkwood JM, Butterfield LH, Tarhini AA, et al. Immunotherapy of cancer in 2012. CA Cancer J Clin 2012;62(5):309-35
83. Pandolfi F, Cianci R, Lolli S, et al. Strategies to overcome obstacles to successful immunotherapy of melanoma. Int J Immunopathol Pharmacol 2008;21:493-500
84. Chen Y-Z, Yao X-L, Tabata Y, et al. Gene carriers and transfection systems used in the recombination of dendritic cells for effective cancer immunotherapy. Clin Dev Immunol 2008;62:565643
85. Kirkwood JM, Lee S, Moschos SJ, et al. Immunogenicity and antitumor effects of vaccination with peptide vaccine +/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern cooperative oncology group phase II trial E1696. Clin Cancer Res 2009;15:1443-51
86. Hashii Y, Sato E, Ohta H, et al. WT1 peptide immunotherapy for cancer in children and young adults. Pediatr Blood Cancer 2010;55:352-5
87. Mackall CL, Rhee EH, Read EJ, et al. A Pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin Cancer Res 2008;14:4850-8
88. Meadors JL, Cui Y, Chen Q-R, et al. Murine rhabdomyosarcoma is immunogenic and responsive to T-cell-based immunotherapy. Pediat Blood Cancer 2011;57:921-9
89. Wrzesinski C, Paulos CM, Kaiser A et al. increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother 2010;33:1-7
90. Iyer U, Kadambi VJ. Antibody drug conjugates-Trojan horses in the war on cancer. J Pharmacol Toxicol Methods 2011;64:207-12
91. Lorberboum-Galski H. Human toxin-based recombinant immunotoxins/chimeric proteins as a drug delivery system for targeted treatment of human diseases. Expert Opin Drug Deliv 2011;8:605-21
92. Fitzgerald DJ, Moskatel E, Ben-josef G et al. Enhancing immunotoxin cell-killing activity via combination therapy with ABT-737. Leuk Lymphoma 2011;52:79-81
93. Litvak-Greenfeld D.Benhar I. Risks and untoward toxicities of antibody-based immunoconjugates Adv Drug Delivery Rev.
94. Litvak-Greenfeld D, Benhar I. Risks and untoward toxicities of antibody-based immunoconjugates. Adv Drug Delivery Rev 94. Mathew M, Verma RS. Humanized immunotoxins: A new generation of immunotoxins for targeted cancer therapy. Cancer Sci 2009;100:1359-65
95. Matthews I, Sims G, Ledwidge S, et al. Antibodies to acetylcholine receptor in parous women with myasthenia: Evidence for immunization by fetal antigen. Lab Invest 2002;82:1407-17 (Pubitemid 35191544)
96. Barth S, Huhn M, Matthey B, et al. Ki-4(scFv)-ETA¢, a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice. Blood 2000;95:3909-14 (Pubitemid 30412867)
97. Gattenlohner S, Jori-en H, Huhn M et al. A human recombinant autoantibody-based immunotoxin specific for the fetal acetylcholine receptor inhibits rhabdomyosarcoma growth in vitro and in a murine transplantation model. J Biomed Biotechnol 2010;2010:187621
98. Kreitman RJ, Pastan I. Antibody fusion proteins: Anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res 2011;17:6398-405
99. Onda M, Beers R, Xiang L, et al. Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes. Proc Natl Acad Sci 2011. 108: 5742-5747
100. Madhumathi J, Verma RS. Therapeutic targets and recent advances in protein immunotoxins. Curr Opin Microbiol. 2011;17(3):300-9
101. Moritz D, Groner B. A spacer region between the single chain antibody and the CD3zeta chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity. Gene Ther 1995;2:539-46
102. Aguilar LK, Guzik BW, Aguilar-Cordova E. Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development. J Cell Biochem 2011;112:1969-77
103. Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion versus functional clonal inactivation: A costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol 1989;7:445-80 (Pubitemid 19138020)
104. Hombach A, Wieczarkowiecz A Marquardt T, et al. Tumor-Specific T Cell Activation by recombinant immunoreceptors: CD3{zeta} Signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3{zeta} signaling receptor molecule. J Immunol 2001;167:6123-31 (Pubitemid 33081538)
105. Kowolik C, Topp M, Gonzalez S, et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 2006;66:10995-1004 (Pubitemid 44876999)
106. Chmielewski M, Hombach AA, Abken H. CD28 cosignalling does not affect the activation threshold in a chimeric antigen receptor-redirected T-cell attack. Gene Ther 2011;18:62-72
107. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2011;19(12):2709-20
108. Park JH, Brentjens RJ. Adoptive immunotherapy for B cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells. Discov Med 2010;9:277-88
109. Landmeier S, Altvater B, Pscherer S et al. Cytotoxic T cells transduced with chimeric anti-CD19 receptors prevent engraftment of primary lymphoblastic leukemia in vivo. Leukemia 2010;24:1080-4
110. Simon-Keller K, Paschen A, Eichmuller S, et al. Adoptive T-zell-therapie des rhabdomyosarkoms. Pathologe 2010;31:215-20
111. Fourcade J, Sun Z, Benallaoua M, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exper Med 2010;207:2175-86
112. Kashkar H, Seeger J-M, Hombach A et al. XIAP targeting sensitizes Hodgkin lymphoma cells for cytolytic T-cell attack. Blood 2006;108:3434-40
113. Seeger JM, Schmidt P, Brinkmann K et al. The proteasome inhibitor bortezomib sensitizes melanoma cells toward adoptive CTL attack cancer res. 2010;70:1825-34
114. Hu D, Liu S, Shi L, et al. Cleavage of survivin by ganzyme M triggers degradation of the survivin-X-linked Inhibitor of Apoptosis Protein (XIAP) complex to free caspase activity leading to cytolysis of target tumor cells. J Biol Chem 2010;285:18326-35
115. Altieri D. Survivin and IAP proteins in cell-death mechanisms. Biochem J 2010;430:199-205
116. Melcher A, Parato K, Rooney CM, Bell JC. Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther 2011;19:1008-16
117. Cattaneo R, Miest T, Shashkova EV Barry MA. Reprogrammed viruses as cancer therapeutics: Targeted, armed and shielded. Nat Rev Micro 2008;6:529-40 (Pubitemid 351850977)
118. Nakamura T, Peng K-W, Harvey M et al. Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotech 2005;23:209-14 (Pubitemid 40255331)
119. Nitzki F, Zibat A, Frommhold A, et al. Uncommitted precursor cells might contribute to increased incidence of embryonal rhabdomyosarcoma in heterozygous Patched1-mutant mice. Oncogene 2011;30:4428-36
120. Kawa S, Onda M, Ho M, et al. The improvement of an anti-CD22 immunotoxin: Conversion to single-chain and disulfide stabilized form and affinity maturation by alanine scan. MABs 2011;3:479-86